Target acquired: Progress and promise of targeted therapeutics in the treatment of prostate cancer

Current Cancer Drug Targets

Volumn 15, Issue 5, 2015, Pages 394-405

  Stuchbery, Ryan ^a   Kurganovs, Natalie J ^b   McCoy, Patrick J ^b   Nelson, Colleen C ^c   Hayes, Vanessa M ^d   Corcoran, Niall M ^a,b,e   Hovens, Christopher M ^a,b,e  

^a Australian Prostate Cancer Research Centre at Epworth   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Translational Research Institute   (Australia)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Precision medicine; Prostate cancer; Targeted therapeutics

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BCR ABL PROTEIN; CETUXIMAB; CRIZOTINIB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; OLAPARIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; PROTEIN P53; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ARTICLE; CELL HETEROGENEITY; DOUBLE STRANDED DNA BREAK; EPIGENETICS; GENE MUTATION; GENE REARRANGEMENT; GENOME; HUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; ANIMAL; DRUG DELIVERY SYSTEM; GENE TARGETING; GENETICS; MALE; MUTATION; PROCEDURES; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; TRENDS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; GENE TARGETING; HUMANS; MALE; MUTATION; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84938687201     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009615666150416113453     Document Type: Article

References (116)

1. [1] Rahman, N.; Stratton, M.R. The genetics of breast cancer susceptibility. Annu. Rev. Genet., 1998, 32, 95-121.
2. [2] Edwards, S.M.; Evans, D.G.; Hope, Q.; Norman, A.R.; Barbachano, Y.; Bullock, S.; Kote-Jarai, Z.; Meitz, J.; Falconer, A.; Osin, P.; Fisher, C.; Guy, M.; Jhavar, S.G.; Hall, A.L.; O’Brien, L.T.; Gehr-Swain, B.N.; Wilkinson, R.A.; Forrest, M.S.; Dearnaley, D.P.; Ardern-Jones, A.T.; Page, E.C.; Easton, D.F.; Eeles, R.A.; Collaborators, U.K.G.P.C.S.; Oncology, B.S.o. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br. J. Cancer, 2010, 103(6), 918-924.
3. [3] Moody, C.A.; Laimins, L.A. Human papillomavirus oncoproteins: pathways to transformation. Nat. Rev. Cancer, 2010, 10(8), 550-560.
4. [4] Carey, R.N.; Driscoll, T.R.; Peters, S.; Glass, D.C.; Reid, A.; Benke, G.; Fritschi, L. Estimated prevalence of exposure to occupational carcinogens in Australia (2011-2012). Occup. Environ. Med., 2014, 71(1), 55-62.
5. [5] Venter, J.C.; Adams, M.D.; Myers, E.W.; Li, P.W.; Mural, R.J.; Sutton, G.G.; Smith, H.O.; Yandell, M.; Evans, C.A.; Holt, R.A.; Gocayne, J.D.; Amanatides, P.; Ballew, R.M.; Huson, D.H.; Wortman, J.R.; Zhang, Q.; Kodira, C.D.; Zheng, X.H.; Chen, L.; Skupski, M.; Subramanian, G.; Thomas, P.D.; Zhang, J.; Gabor Miklos, G.L.; Nelson, C.; Broder, S.; Clark, A.G.; Nadeau, J.; McKusick, V.A.; Zinder, N.; Levine, A.J.; Roberts, R.J.; Simon, M.; Slayman, C.; Hunkapiller, M.; Bolanos, R.; Delcher, A.; Dew, I.; Fasulo, D.; Flanigan, M.; Florea, L.; Halpern, A.; Hannenhalli, S.; Kravitz, S.; Levy, S.; Mobarry, C.; Reinert, K.; Remington, K.; Abu-Threideh, J.; Beasley, E.; Biddick, K.; Bonazzi, V.; Brandon, R.; Cargill, M.; Chandramouliswaran, I.; Charlab, R.; Chaturvedi, K.; Deng, Z.; Di Francesco, V.; Dunn, P.; Eilbeck, K.; Evangelista, C.; Gabrielian, A.E.; Gan, W.; Ge, W.; Gong, F.; Gu, Z.; Guan, P.; Heiman, T.J.; Higgins, M.E.; Ji, R.R.; Ke, Z.; Ketchum, K.A.; Lai, Z.; Lei, Y.; Li, Z.; Li, J.; Liang, Y.; Lin, X.; Lu, F.; Merkulov, G.V.; Milshina, N.; Moore, H.M.; Naik, A.K.; Narayan, V.A.; Neelam, B.; Nusskern, D.; Rusch, D.B.; Salzberg, S.; Shao, W.; Shue, B.; Sun, J.; Wang, Z.; Wang, A.; Wang, X.; Wang, J.; Wei, M.; Wides, R.; Xiao, C.; Yan, C.; Yao, A.; Ye, J.; Zhan, M.; Zhang, W.; Zhang, H.; Zhao, Q.; Zheng, L.; Zhong, F.; Zhong, W.; Zhu, S.; Zhao, S.; Gilbert, D.; Baumhueter, S.; Spier, G.; Carter, C.; Cravchik, A.; Woodage, T.; Ali, F.; An, H.; Awe, A.; Baldwin, D.; Baden, H.; Barnstead, M.; Barrow, I.; Beeson, K.; Busam, D.; Carver, A.; Center, A.; Cheng, M.L.; Curry, L.; Danaher, S.; Davenport, L.; Desilets, R.; Dietz, S.; Dodson, K.; Doup, L.; Ferriera, S.; Garg, N.; Gluecksmann, A.; Hart, B.; Haynes, J.; Haynes, C.; Heiner, C.; Hladun, S.; Hostin, D.; Houck, J.; Howland, T.; Ibegwam, C.; Johnson, J.; Kalush, F.; Kline, L.; Koduru, S.; Love, A.; Mann, F.; May, D.; McCawley, S.; McIntosh, T.; McMullen, I.; Moy, M.; Moy, L.; Murphy, B.; Nelson, K.; Pfannkoch, C.; Pratts, E.; Puri, V.; Qureshi, H.; Reardon, M.; Rodriguez, R.; Rogers, Y.H.; Romblad, D.; Ruhfel, B.; Scott, R.; Sitter, C.; Smallwood, M.; Stewart, E.; Strong, R.; Suh, E.; Thomas, R.; Tint, N.N.; Tse, S.; Vech, C.; Wang, G.; Wetter, J.; Williams, S.; Williams, M.; Windsor, S.; Winn-Deen, E.; Wolfe, K.; Zaveri, J.; Zaveri, K.; Abril, J.F.; Guigo, R.; Campbell, M.J.; Sjolander, K.V.; Karlak, B.; Kejariwal, A.; Mi, H.; Lazareva, B.; Hatton, T.; Narechania, A.; Diemer, K.; Muruganujan, A.; Guo, N.; Sato, S.; Bafna, V.; Istrail, S.; Lippert, R.; Schwartz, R.; Walenz, B.; Yooseph, S.; Allen, D.; Basu, A.; Baxendale, J.; Blick, L.; Caminha, M.; Carnes-Stine, J.; Caulk, P.; Chiang, Y.H.; Coyne, M.; Dahlke, C.; Mays, A.; Dombroski, M.; Donnelly, M.; Ely, D.; Esparham, S.; Fosler, C.; Gire, H.; Glanowski, S.; Glasser, K.; Glodek, A.; Gorokhov, M.; Graham, K.; Gropman, B.; Harris, M.; Heil, J.; Henderson, S.; Hoover, J.; Jennings, D.; Jordan, C.; Jordan, J.; Kasha, J.; Kagan, L.; Kraft, C.; Levitsky, A.; Lewis, M.; Liu, X.; Lopez, J.; Ma, D.; Majoros, W.; McDaniel, J.; Murphy, S.; Newman, M.; Nguyen, T.; Nguyen, N.; Nodell, M.; Pan, S.; Peck, J.; Peterson, M.; Rowe, W.; Sanders, R.; Scott, J.; Simpson, M.; Smith, T.; Sprague, A.; Stockwell, T.; Turner, R.; Venter, E.; Wang, M.; Wen, M.; Wu, D.; Wu, M.; Xia, A.; Zandieh, A.; Zhu, X. The sequence of the human genome. Science, 2001, 291(5507), 1304-1351.
6. [6] Lander, E.S.; Linton, L.M.; Birren, B.; Nusbaum, C.; Zody, M.C.; Baldwin, J.; Devon, K.; Dewar, K.; Doyle, M.; FitzHugh, W.; Funke, R.; Gage, D.; Harris, K.; Heaford, A.; Howland, J.; Kann, L.; Lehoczky, J.; LeVine, R.; McEwan, P.; McKernan, K.; Meldrim, J.; Mesirov, J.P.; Miranda, C.; Morris, W.; Naylor, J.; Raymond, C.; Rosetti, M.; Santos, R.; Sheridan, A.; Sougnez, C.; Stange-Thomann, N.; Stojanovic, N.; Subramanian, A.; Wyman, D.; Rogers, J.; Sulston, J.; Ainscough, R.; Beck, S.; Bentley, D.; Burton, J.; Clee, C.; Carter, N.; Coulson, A.; Deadman, R.; Deloukas, P.; Dunham, A.; Dunham, I.; Durbin, R.; French, L.; Grafham, D.; Gregory, S.; Hubbard, T.; Humphray, S.; Hunt, A.; Jones, M.; Lloyd, C.; McMurray, A.; Matthews, L.; Mercer, S.; Milne, S.; Mullikin, J.C.; Mungall, A.; Plumb, R.; Ross, M.; Shownkeen, R.; Sims, S.; Waterston, R.H.; Wilson, R.K.; Hillier, L.W.; McPherson, J.D.; Marra, M.A.; Mardis, E.R.; Fulton, L.A.; Chinwalla, A.T.; Pepin, K.H.; Gish, W.R.; Chissoe, S.L.; Wendl, M.C.; Delehaunty, K.D.; Miner, T.L.; Delehaunty, A.; Kramer, J.B.; Cook, L.L.; Fulton, R.S.; Johnson, D.L.; Minx, P.J.; Clifton, S.W.; Hawkins, T.; Branscomb, E.; Predki, P.; Richardson, P.; Wenning, S.; Slezak, T.; Doggett, N.; Cheng, J.F.; Olsen, A.; Lucas, S.; Elkin, C.; Uberbacher, E.; Frazier, M.; Gibbs, R.A.; Muzny, D.M.; Scherer, S.E.; Bouck, J.B.; Sodergren, E.J.; Worley, K.C.; Rives, C.M.; Gorrell, J.H.; Metzker, M.L.; Naylor, S.L.; Kucherlapati, R.S.; Nelson, D.L.; Weinstock, G.M.; Sakaki, Y.; Fujiyama, A.; Hattori, M.; Yada, T.; Toyoda, A.; Itoh, T.; Kawagoe, C.; Watanabe, H.; Totoki, Y.; Taylor, T.; Weissenbach, J.; Heilig, R.; Saurin, W.; Artiguenave, F.; Brottier, P.; Bruls, T.; Pelletier, E.; Robert, C.; Wincker, P.; Smith, D.R.; Doucette-Stamm, L.; Rubenfield, M.; Weinstock, K.; Lee, H.M.; Dubois, J.; Rosenthal, A.; Platzer, M.; Nyakatura, G.; Taudien, S.; Rump, A.; Yang, H.; Yu, J.; Wang, J.; Huang, G.; Gu, J.; Hood, L.; Rowen, L.; Madan, A.; Qin, S.; Davis, R.W.; Federspiel, N.A.; Abola, A.P.; Proctor, M.J.; Myers, R.M.; Schmutz, J.; Dickson, M.; Grimwood, J.; Cox, D.R.; Olson, M.V.; Kaul, R.; Raymond, C.; Shimizu, N.; Kawasaki, K.; Minoshima, S.; Evans, G.A.; Athanasiou, M.; Schultz, R.; Roe, B.A.; Chen, F.; Pan, H.; Ramser, J.; Lehrach, H.; Reinhardt, R.; McCombie, W.R.; de la Bastide, M.; Dedhia, N.; Blocker, H.; Hornischer, K.; Nordsiek, G.; Agarwala, R.; Aravind, L.; Bailey, J.A.; Bateman, A.; Batzoglou, S.; Birney, E.; Bork, P.; Brown, D.G.; Burge, C.B.; Cerutti, L.; Chen, H.C.; Church, D.; Clamp, M.; Copley, R.R.; Doerks, T.; Eddy, S.R.; Eichler, E.E.; Furey, T.S.; Galagan, J.; Gilbert, J.G.; Harmon, C.; Hayashizaki, Y.; Haussler, D.; Hermjakob, H.; Hokamp, K.; Jang, W.; Johnson, L.S.; Jones, T.A.; Kasif, S.; Kaspryzk, A.; Kennedy, S.; Kent, W.J.; Kitts, P.; Koonin, E.V.; Korf, I.; Kulp, D.; Lancet, D.; Lowe, T.M.; McLysaght, A.; Mikkelsen, T.; Moran, J.V.; Mulder, N.; Pollara, V.J.; Ponting, C.P.; Schuler, G.; Schultz, J.; Slater, G.; Smit, A.F.; Stupka, E.; Szustakowski, J.; Thierry-Mieg, D.; Thierry-Mieg, J.; Wagner, L.; Wallis, J.; Wheeler, R.; Williams, A.; Wolf, Y.I.; Wolfe, K.H.; Yang, S.P.; Yeh, R.F.; Collins, F.; Guyer, M.S.; Peterson, J.; Felsenfeld, A.; Wetterstrand, K.A.; Patrinos, A.; Morgan, M.J.; de Jong, P.; Catanese, J.J.; Osoegawa, K.; Shizuya, H.; Choi, S.; Chen, Y.J.; International Human Genome Sequencing, C. Initial sequencing and analysis of the human genome. Nature, 2001, 409(6822), 860-921.
7. [7] HiSeqX Ten: $1000 Human genome and extreme throughput for population scale sequencing. http://support.illumina.com/sequencing/sequencing_instruments/hiseq-x/documentation.html.
8. [8] Mardis, E.R. The $1,000 genome, the $100,000 analysis? Genome Med., 2010, 2(11), 84.
9. [9] Meadows, M. Genomics and personalized medicine. FDA Consumer, 2005, 39(6), 12-17.
10. [10] Garrod, A.E. About Alkaptonuria. Med. Chir. Trans., 1902, 85, 69-78.
11. [11] Alving, A.S.; Carson, P.E.; Flanagan, C.L.; Ickes, C.E. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science, 1956, 124(3220), 484-485.
12. [12] Administration, U.F.a.D. Draft guidance for industry and Food and Drug Administration Staff: In vitro companion diagnostic devices. [Report], 2011: 1-13. Available from: http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM262327.pdf. (cited: 25 June 2014).
13. [13] Scardino, P.T.; Weaver, R.; Hudson, M.A. Early detection of prostate cancer. Hum. Pathol., 1992, 23(3), 211-222.
14. [14] Cooperberg, M.R.; Lubeck, D.P.; Meng, M.V.; Mehta, S.S.; Carroll, P.R. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J. Clin. Oncol. 2004, 22(11), 2141-2149.
15. [15] Bastian, P.J.; Gonzalgo, M.L.; Aronson, W.J.; Terris, M.K.; Kane, C.J.; Amling, C.L.; Presti, J.C., Jr.; Mangold, L.A.; Humphreys, E.; Epstein, J.I.; Partin, A.W.; Freedland, S.J. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer, 2006, 107(6), 1265-1272.
16. [16] Grimm, P.; Billiet, I.; Bostwick, D.; Dicker, A.P.; Frank, S.; Immerzeel, J.; Keyes, M.; Kupelian, P.; Lee, W.R.; Machtens, S.; Mayadev, J.; Moran, B.J.; Merrick, G.; Millar, J.; Roach, M.; Stock, R.; Shinohara, K.; Scholz, M.; Weber, E.; Zietman, A.; Zelefsky, M.; Wong, J.; Wentworth, S.; Vera, R.; Langley, S. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int., 2012, 109(1), 22-29.
17. [17] Klotz, L. Active surveillance for prostate cancer: overview and update. Curr. Treat Options Oncol., 2013, 14(1), 97-108.
18. [18] Berger, M.F.; Lawrence, M.S.; Demichelis, F.; Drier, Y.; Cibulskis, K.; Sivachenko, A.Y.; Sboner, A.; Esgueva, R.; Pflueger, D.; Sougnez, C.; Onofrio, R.; Carter, S.L.; Park, K.; Habegger, L.; Ambrogio, L.; Fennell, T.; Parkin, M.; Saksena, G.; Voet, D.; Ramos, A.H.; Pugh, T.J.; Wilkinson, J.; Fisher, S.; Winckler, W.; Mahan, S.; Ardlie, K.; Baldwin, J.; Simons, J.W.; Kitabayashi, N.; MacDonald, T.Y.; Kantoff, P.W.; Chin, L.; Gabriel, S.B.; Gerstein, M.B.; Golub, T.R.; Meyerson, M.; Tewari, A.; Lander, E.S.; Getz, G.; Rubin, M.A.; Garraway, L.A. The genomic complexity of primary human prostate cancer. Nature, 2011, 470(7333), 214-220.
19. [19] Mok, T.S.; Wu, Y.L.; Thongprasert, S.; Yang, C.H.; Chu, D.T.; Saijo, N.; Sunpaweravong, P.; Han, B.; Margono, B.; Ichinose, Y.; Nishiwaki, Y.; Ohe, Y.; Yang, J.J.; Chewaskulyong, B.; Jiang, H.; Duffield, E.L.; Watkins, C.L.; Armour, A.A.; Fukuoka, M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med., 2009, 361(10), 947-957.
20. [20] Cooper, C.S.; Foster, C.S. Concepts of epigenetics in prostate cancer development. Br. J. Cancer, 2009, 100(2), 240-245.
21. [21] Yoshimoto, M.; Ding, K.; Sweet, J.M.; Ludkovski, O.; Trottier, G.; Song, K.S.; Joshua, A.M.; Fleshner, N.E.; Squire, J.A.; Evans, A.J. PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade. Mod. Pathol., 2013, 26(3), 435-47.
22. [22] Fialkow, P.J. Clonal origin of human tumors. Ann. Rev. Med., 1979, 30, 135-143.
23. [23] Shattuck, T.M.; Westra, W.H.; Ladenson, P.W.; Arnold, A. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N. Engl. J. Med. 2005, 352(23), 2406-2412.
24. [24] Wang, X.; Wang, M.; MacLennan, G.T.; Abdul-Karim, F.W.; Eble, J.N.; Jones, T.D.; Olobatuyi, F.; Eisenberg, R.; Cummings, O.W.; Zhang, S.; Lopez-Beltran, A.; Montironi, R.; Zheng, S.; Lin, H.; Davidson, D.D.; Cheng, L. Evidence for common clonal origin of multifocal lung cancers. J. Natl. Cancer. Inst., 2009, 101(8), 560-570.
25. [25] Villers, A.; McNeal, J.E.; Freiha, F.S.; Stamey, T.A. Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer, 1992, 70(9), 2313-2318.
26. [26] Wolters, T.; Montironi, R.; Mazzucchelli, R.; Scarpelli, M.; Roobol, M.J.; van den Bergh, R.C.; van Leeuwen, P.J.; Hoedemaeker, R.F.; van Leenders, G.J.; Schroder, F.H.; van der Kwast, T.H. Comparison of incidentally detected prostate cancer with screen-detected prostate cancer treated by prostatectomy. Prostate, 2012, 72(1), 108-115.
27. [27] Baca, S.C.; Prandi, D.; Lawrence, M.S.; Mosquera, J.M.; Romanel, A.; Drier, Y.; Park, K.; Kitabayashi, N.; MacDonald, T.Y.; Ghandi, M.; Van Allen, E.; Kryukov, G.V.; Sboner, A.; Theurillat, J.P.; Soong, T.D.; Nickerson, E.; Auclair, D.; Tewari, A.; Beltran, H.; Onofrio, R.C.; Boysen, G.; Guiducci, C.; Barbieri, C.E.; Cibulskis, K.; Sivachenko, A.; Carter, S.L.; Saksena, G.; Voet, D.; Ramos, A.H.; Winckler, W.; Cipicchio, M.; Ardlie, K.; Kantoff, P.W.; Berger, M.F.; Gabriel, S.B.; Golub, T.R.; Meyerson, M.; Lander, E.S.; Elemento, O.; Getz, G.; Demichelis, F.; Rubin, M.A.; Garraway, L.A. Punctuated evolution of prostate cancer genomes. Cell, 2013, 153(3), 666-677.
28. [28] Ibeawuchi, C.; Schmidt, H.; Voss, R.; Titze, U.; Abbas, M.; Neumann, J.; Eltze, E.; Hoogland, A.M.; Jenster, G.; Brandt, B.; Semjonow, A. Genome-wide investigation of multifocal and unifocal prostate cancer-are they genetically different? Int. J. Mol. Sci., 2013, 14(6), 11816-11829.
29. [29] Lindberg, J.; Klevebring, D.; Liu, W.; Neiman, M.; Xu, J.; Wiklund, P.; Wiklund, F.; Mills, I.G.; Egevad, L.; Gronberg, H. Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. Eur. Urol., 2013, 63(2), 347-353.
30. [30] Boyd, L.K.; Mao, X.; Xue, L.; Lin, D.; Chaplin, T.; Kudahetti, S.C.; Stankiewicz, E.; Yu, Y.; Beltran, L.; Shaw, G.; Hines, J.; Oliver, R.T.; Berney, D.M.; Young, B.D.; Lu, Y.J. High-resolution genome-wide copy-number analysis suggests a monoclonal origin of multifocal prostate cancer. Genes Chromosomes Cancer, 2012, 51(6), 579-589.
31. [31] Hong, M.K.H.; Macintyre, G.; Wedge, D.C.; Van Loo, P.; Patel, K.; Lunke, S.; Alexandrov, L.B.; Sloggett, C.; Cmero, M.; Marass, F.; Tsui, D.; Mangiola, S.; Lonie, A.; Naeem, H.; Sapre, N.; Phal, P.M.; Kurganovs, N.; Chin, X.; Kerger, M.; Warren, A.Y.; Neal, D.; Gnanapragasam, V.; Rosenfeld, N.; Pedersen, J.S.; Ryan, A.; Haviv, I.; Costello, A.J.; Corcoran, N.M.; Hovens, C.M. Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat. Commun., 2015, 6.
32. [32] Liu, W.; Laitinen, S.; Khan, S.; Vihinen, M.; Kowalski, J.; Yu, G.; Chen, L.; Ewing, C.M.; Eisenberger, M.A.; Carducci, M.A.; Nelson, W.G.; Yegnasubramanian, S.; Luo, J.; Wang, Y.; Xu, J.; Isaacs, W.B.; Visakorpi, T.; Bova, G.S. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat. Med. 2009, 15(5), 559-565.
33. [33] Normanno, N.; De Luca, A.; Bianco, C.; Strizzi, L.; Mancino, M.; Maiello, M.R.; Carotenuto, A.; De Feo, G.; Caponigro, F.; Salomon, D.S. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene, 2006, 366(1), 2-16.
34. [34] Antonicelli, A.; Cafarotti, S.; Indini, A.; Galli, A.; Russo, A.; Cesario, A.; Lococo, F.M.; Russo, P.; Mainini, A.F.; Bonifati, L.G.; Nosotti, M.; Santambrogio, L.; Margaritora, S.; Granone, P.M.; Dutly, A.E. EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation. Int. J. Med. Sci., 2013, 10(3), 320-330.
35. [35] Peraldo-Neia, C.; Migliardi, G.; Mello-Grand, M.; Montemurro, F.; Segir, R.; Pignochino, Y.; Cavalloni, G.; Torchio, B.; Mosso, L.; Chiorino, G.; Aglietta, M. Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. BMC Cancer, 2011, 11, 31.
36. [36] Fu, M.; Zhang, W.; Shan, L.; Song, J.; Shang, D.; Ying, J.; Zhao, J. Mutation status of somatic EGFR and KRAS genes in Chinese patients with prostate cancer (PCa). Virchows Arch, 2014, 464(5), 575-581.
37. [37] Marks, R.A.; Zhang, S.; Montironi, R.; McCarthy, R.P.; MacLennan, G.T.; Lopez-Beltran, A.; Jiang, Z.; Zhou, H.; Zheng, S.; Davidson, D.D.; Baldridge, L.A.; Cheng, L. Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: a fluorescence in situ hybridization and immunohistochemical analysis. Prostate, 2008, 68(9), 919-923.
38. [38] Canil, C.M.; Moore, M.J.; Winquist, E.; Baetz, T.; Pollak, M.; Chi, K.N.; Berry, S.; Ernst, D.S.; Douglas, L.; Brundage, M.; Fisher, B.; McKenna, A.; Seymour, L. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J. Clin. Oncol., 2005, 23(3), 455-60.
39. [39] Carrion-Salip, D.; Panosa, C.; Menendez, J.A.; Puig, T.; Oliveras, G.; Pandiella, A.; De Llorens, R.; Massaguer, A. Androgenindependent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. Int. J. Oncol., 2012, 41(3), 1128-38.
40. [40] Gravina, G.L.; Marampon, F.; Piccolella, M.; Biordi, L.; Ficorella, C.; Motta, M.; Jannini, E.A.; Tombolini, V.; Festuccia, C. Antitumor effects of carnertinib in castration resistant prostate cancer models: A Comparative study with erlotinib. Prostate, 2011.
41. [41] Chen, L.; Mooso, B.A.; Jathal, M.K.; Madhav, A.; Johnson, S.D.; van Spyk, E.; Mikhailova, M.; Zierenberg-Ripoll, A.; Xue, L.; Vinall, R.L.; deVere White, R.W.; Ghosh, P.M. Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3. Clin. Cancer Res., 2011, 17(19), 6218-6228.
42. [42] Goldenberg, M.M. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin. Ther., 1999, 21(2), 309-318.
43. [43] Tagliabue, E.; Campiglio, M.; Pupa, S.M.; Menard, S.; Balsari, A. Activity and resistance of trastuzumab according to different clinical settings. Cancer Treat Rev., 2012, 38(3), 212-217.
44. [44] Siampanopoulou, M.; Galaktidou, G.; Dimasis, N.; Gotzamani-Psarrakou, A. Profiling serum HER-2/NEU in prostate cancer. Hippokratia, 2013, 17(2), 108-112.
45. [45] Guyader, C.; Ceraline, J.; Gravier, E.; Morin, A.; Michel, S.; Erdmann, E.; de Pinieux, G.; Cabon, F.; Bergerat, J.P.; Poupon, M.F.; Oudard, S. Risk of hormone escape in a human prostate cancer model depends on therapy modalities and can be reduced by tyrosine kinase inhibitors. PLoS One, 2012, 7(8), 42252.
46. [46] Carlsson, J.; Shen, L.; Xiang, J.; Xu, J.; Wei, Q. Tendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors. Oncol. Lett., 2013, 5(1), 208-14.
47. [47] Whang, Y.E.; Armstrong, A.J.; Rathmell, W.K.; Godley, P.A.; Kim, W.Y.; Pruthi, R.S.; Wallen, E.M.; Crane, J.M.; Moore, D.T.; Grigson, G.; Morris, K.; Watkins, C.P.; George, D.J. A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. Urol. Oncol., 2013, 31(1), 82-6.
48. [48] de Bono, J.S.; Bellmunt, J.; Attard, G.; Droz, J.P.; Miller, K.; Flechon, A.; Sternberg, C.; Parker, C.; Zugmaier, G.; Hersberger-Gimenez, V.; Cockey, L.; Mason, M.; Graham, J. Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormonerefractory prostate cancer. J. Clin. Oncol., 2007, 25(3), 257-262.
49. [49] Agus, D.B.; Sweeney, C.J.; Morris, M.J.; Mendelson, D.S.; McNeel, D.G.; Ahmann, F.R.; Wang, J.; Derynck, M.K.; Ng, K.; Lyons, B.; Allison, D.E.; Kattan, M.W.; Scher, H.I. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxanebased therapy. J. Clin. Oncol., 2007, 25(6), 675-681.
50. [50] Douillard, J.Y.; Sobrero, A.; Carnaghi, C.; Comella, P.; Diaz-Rubio, E.; Santoro, A.; Van Cutsem, E. Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy. Ann. Oncol., 2003, 14(2), 7-12.
51. [51] Meyerhardt, J.A.; Mayer, R.J. Systemic therapy for colorectal cancer. N. Engl. J. Med., 2005, 352(5), 476-487.
52. [52] Baselga, J. The EGFR as a target for anticancer therapy--focus on cetuximab. Eur. J. Cancer, 2001, 37(4), 16-22.
53. [53] Lièvre, A.; Bachet, J.B.; Le Corre, D.; Boige, V.; Landi, B.; Emile, J.F.; Côté, J.F.; Tomasic, G.; Penna, C.; Ducreux, M.; Rougier, P.; Penault-Llorca, F.; Laurent-Puig, P. KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer. Cancer Res., 2006, 66(8), 3992-3995.
54. [54] Bouali, S.; Chrétien, A.S.; Ramacci, C.; Rouyer, M.; Becuwe, P.; Merlin, J.L. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signalling in KRAS wild-type, hormone refractory prostate cancer cells. Oncol. Rep., 2009, 21, 731-35.
55. [55] Festuccia, C.; Angelucci, A.; Gravina, G.L.; Biordi, L.; Millimaggi, D.; Muzi, P.; Vicentini, C.; Bologna, M. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinasetype plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination. Throm. Haemost., 2005, 93(5), 964-975.
56. [56] Cathomas, R.; Rothermundt, C.; Klingbiel, D.; Bubendorf, L.; Jaggi, R.; Betticher, D.C.; Brauchli, P.; Cotting, D.; Droege, C.; Winterhalder, R.; Siciliano, D.; Berthold, D.R.; Pless, M.; Schiess, R.; von Moos, R.; Gillessen, S.; Swiss Group for Clinical Cancer Research, S. Efficacy of cetuximab in metastatic castrationresistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07). Clin. Cancer Res., 2012, 18(21), 6049-6057.
57. [57] Liu, P.; Cheng, H.; Roberts, T.M.; Zhao, J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Dis., 2009, 8(8), 627-644.
58. [58] Brugge, J.; Hung, M.C.; Mills, G.B. A new mutational AKTivation in the PI3K pathway. Cancer Cell, 2007, 12(2), 104-107.
59. [59] Dowling, R.J.; Topisirovic, I.; Fonseca, B.D.; Sonenberg, N. Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim. Biophys. Acta., 2010, 1804(3), 433-439.
60. [60] Sato, T.; Nakashima, A.; Guo, L.; Coffman, K.; Tamanoi, F. Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene, 2010, 29(18), 2746-2752.
61. [61] Knight, Z.A.; Shokat, K.M. Chemically targeting the PI3K family. Biochem. Soc. Trans., 2007, 35(2), 245-249.
62. [62] Andre, F.; O’Regan, R.; Ozguroglu, M.; Toi, M.; Xu, B.; Jerusalem, G.; Masuda, N.; Wilks, S.; Arena, F.; Isaacs, C.; Yap, Y.S.; Papai, Z.; Lang, I.; Armstrong, A.; Lerzo, G.; White, M.; Shen, K.; Litton, J.; Chen, D.; Zhang, Y.; Ali, S.; Taran, T.; Gianni, L. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol., 2014, 15(6), 580-591.
63. [63] Rizzo, M.; Facchini, G.; Savastano, C.; Lorenzo, G.D.; Lucia, L.D.; Maiorino, L.; Casale, B.; Grimaldi, G.; Formato, R.; Febbraro, A.; Carteni, G. Everolimus as second-line therapy for metastatic renal cell carcinoma: a ‘real-life’ study. Future Oncol., 2014, 1-6.
64. [64] cBioPortal for Cancer Genomics. The Cancer Genome Atlas. http://www.cbioportal.org/public-portal/ (cited: 07 August 2014).
65. [65] Kosaka, T.; Miyajima, A.; Shirotake, S.; Suzuki, E.; Kikuchi, E.; Oya, M. Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer. J. Urol., 2011, 185(6), 2376-2381.
66. [66] Bitting, R.L.; Armstrong, A.J. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocrine-related Cancer 2013, 20(3), R83-99.
67. [67] Amato, R.J.; Jac, J.; Mohammad, T.; Saxena, S. Pilot study of rapamycin in patients with hormone-refractory prostate cancer. Endocr. Relat. Cancer, 2008, 6(2), 97-102.
68. [68] Armstrong, A.J.; Netto, G.J.; Rudek, M.A.; Halabi, S.; Wood, D.P.; Creel, P.A.; Mundy, K.; Davis, S.L.; Wang, T.; Albadine, R.; Schultz, L.; Partin, A.W.; Jimeno, A.; Fedor, H.; Febbo, P.G.; George, D.J.; Gurganus, R.; De Marzo, A.M.; Carducci, M.A. A pharmacodynamic study of rapamycin in men with intermediate-to high-risk localized prostate cancer. Clin. Cancer Res., 2010, 16(11), 3057-3066.
69. [69] Sarbassov, D.D.; Ali, S.M.; Sengupta, S.; Sheen, J.H.; Hsu, P.P.; Bagley, A.F.; Markhard, A.L.; Sabatini, D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 2006, 22(2), 159-168.
70. [70] Yasumizu, Y.; Miyajima, A.; Kosaka, T.; Miyazaki, Y.; Kikuchi, E.; Oya, M. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer. J. Urol., 2014, 191(1), 227-234.
71. [71] Park, H.S.; Hong, S.K.; Oh, M.M.; Yoon, C.Y.; Jeong, S.J.; Byun, S.S.; Cheon, J.; Lee, S.E.; Moon du, G. Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells. Anticancer Res., 2014, 34(7), 3457-3468.
72. [72] Zhu, W.; Fu, W.; Hu, L. NVP-BEZ235, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, prominently enhances radiosensitivity of prostate cancer cell line PC-3. Cancer Biother. Radiopharm., 2013, 28(9), 665-673.
73. [73] Hong, S.W.; Shin, J.S.; Moon, J.H.; Kim, Y.S.; Lee, J.; Choi, E.K.; Ha, S.H.; Lee, D.H.; Chung, H.N.; Kim, J.E.; Kim, K.P.; Hong, Y.S.; Lee, J.L.; Lee, W.J.; Choi, E.K.; Lee, J.S.; Jin, D.H.; Kim, T.W. NVP-BEZ235, a dual PI3K/mTOR inhibitor, induces cell death through alternate routes in prostate cancer cells depending on the PTEN genotype. Apoptosis, 2014, 19(5), 895-904.
74. [74] Ali, I.U.; Schriml, L.M.; Dean, M. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J. Nat. Cancer Inst., 1999, 91(22), 1922-1932.
75. [75] Chen, M.; Pratt, C.P.; Zeeman, M.E.; Schultz, N.; Taylor, B.S.; O’Neill, A.; Castillo-Martin, M.; Nowak, D.G.; Naguib, A.; Grace, D.M.; Murn, J.; Navin, N.; Atwal, G.S.; Sander, C.; Gerald, W.L.; Cordon-Cardo, C.; Newton, A.C.; Carver, B.S.; Trotman, L.C. Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. Cancer cell, 2011, 20(2), 173-186.
76. [76] McMenamin, M.E.; Soung, P.; Perera, S.; Kaplan, I.; Loda, M.; Sellers, W.R. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res, 1999, 59(17), 4291-4296.
77. [77] Giri, D.; Ittmann, M. Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma. Hum. Pathol., 1999, 30(4), 419-424.
78. [78] Lotan, T.L.; Gurel, B.; Sutcliffe, S.; Esopi, D.; Liu, W.; Xu, J.; Hicks, J.L.; Park, B.H.; Humphreys, E.; Partin, A.W.; Han, M.; Netto, G.J.; Isaacs, W.B.; De Marzo, A.M. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin. Cancer Res., 2011, 17(20), 6563-6573.
79. [79] Halvorsen, O.J.; Haukaas, S.A.; Akslen, L.A. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin. Cancer Res., 2003, 9(4), 1474-1479.
80. [80] Chen, Z.; Trotman, L.C.; Shaffer, D.; Lin, H.K.; Dotan, Z.A.; Niki, M.; Koutcher, J.A.; Scher, H.I.; Ludwig, T.; Gerald, W.; Cordon-Cardo, C.; Pandolfi, P.P. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature, 2005, 436(7051), 725-730.
81. [81] Naguib, A.; Trotman, L.C. PTEN plasticity: how the taming of a lethal gene can go too far. Trends Cell Biol., 2013, 23(8), 374-379.
82. [82] Shaw, A.T.; Yeap, B.Y.; Mino-Kenudson, M.; Digumarthy, S.R.; Costa, D.B.; Heist, R.S.; Solomon, B.; Stubbs, H.; Admane, S.; McDermott, U.; Settleman, J.; Kobayashi, S.; Mark, E.J.; Rodig, S.J.; Chirieac, L.R.; Kwak, E.L.; Lynch, T.J.; Iafrate, A.J. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol., 2009, 27(26), 4247-4253.
83. [83] Shaw, A.T.; Kim, D.W.; Nakagawa, K.; Seto, T.; Crino, L.; Ahn, M.J.; De Pas, T.; Besse, B.; Solomon, B.J.; Blackhall, F.; Wu, Y.L.; Thomas, M.; O’Byrne, K.J.; Moro-Sibilot, D.; Camidge, D.R.; Mok, T.; Hirsh, V.; Riely, G.J.; Iyer, S.; Tassell, V.; Polli, A.; Wilner, K.D.; Janne, P.A. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med., 2013, 368(25), 2385-2394.
84. [84] Choi, Y.L.; Soda, M.; Yamashita, Y.; Ueno, T.; Takashima, J.; Nakajima, T.; Yatabe, Y.; Takeuchi, K.; Hamada, T.; Haruta, H.; Ishikawa, Y.; Kimura, H.; Mitsudomi, T.; Tanio, Y.; Mano, H.; Group, A.L.K.L.C.S. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med., 2010, 363(18), 1734-1739.
85. [85] Shen, L.; Ji, H.F. More on crizotinib. N. Engl. J. Med., 2011, 364(8), 777-778.
86. [86] Sun, H.Y.; Ji, F.Q. A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK. Biochem. Biophys. Res. Comm., 2012, 423(2), 319-324.
87. [87] Drake, J.M.; Graham, N.A.; Lee, J.K.; Stoyanova, T.; Faltermeier, C.M.; Sud, S.; Titz, B.; Huang, J.; Pienta, K.J.; Graeber, T.G.; Witte, O.N. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc. Natl. Acad. Sci. USA., 2013, 110(49), 4762-4769.
88. [88] de Klein, A.; van Kessel, A.G.; Grosveld, G.; Bartram, C.R.; Hagemeijer, A.; Bootsma, D.; Spurr, N.K.; Heisterkamp, N.; Groffen, J.; Stephenson, J.R. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature, 1982, 300(5894), 765-767.
89. [89] Heisterkamp, N.; Stam, K.; Groffen, J.; de Klein, A.; Grosveld, G. Structural organization of the bcr gene and its role in the Ph’ translocation. Nature, 1985, 315(6022), 758-761.
90. [90] McWhirter, J.R.; Galasso, D.L.; Wang, J.Y. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol. Cell Biol., 1993, 13(12), 7587-7595.
91. [91] Nowell, P.C.; Hungerford, D.A. Chromosome studies on normal and leukemic human leukocytes. J. Natl. Cancer Inst., 1960, 25, 85-109.
92. [92] Buchdunger, E.; Zimmermann, J.; Mett, H.; Meyer, T.; Muller, M.; Druker, B.J.; Lydon, N.B. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res., 1996, 56(1), 100-104.
93. [93] Kelley, R.K.; Hwang, J.; Magbanua, M.J.; Watt, L.; Beumer, J.H.; Christner, S.M.; Baruchel, S.; Wu, B.; Fong, L.; Yeh, B.M.; Moore, A.P.; Ko, A.H.; Korn, W.M.; Rajpal, S.; Park, J.W.; Tempero, M.A.; Venook, A.P.; Bergsland, E.K. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br. J. Cancer, 2013, 109(7), 1725-1734.
94. [94] Gambacorti-Passerini, C.; Antolini, L.; Mahon, F.X.; Guilhot, F.; Deininger, M.; Fava, C.; Nagler, A.; Della Casa, C.M.; Morra, E.; Abruzzese, E.; D’Emilio, A.; Stagno, F.; le Coutre, P.; Hurtado-Monroy, R.; Santini, V.; Martino, B.; Pane, F.; Piccin, A.; Giraldo, P.; Assouline, S.; Durosinmi, M.A.; Leeksma, O.; Pogliani, E.M.; Puttini, M.; Jang, E.; Reiffers, J.; Valsecchi, M.G.; Kim, D.W. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J. Natl. Cancer Inst., 2011, 103(7), 553-561.
95. [95] Al-Jamal, H.A.; Jusoh, S.A.; Yong, A.C.; Asan, J.M.; Hassan, R.; Johan, M.F. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells. Asian Pacific journal of cancer prevention: APJCP, 2014, 15(11), 4555-4561.
96. [96] Jackson, R.C.; Radivoyevitch, T. A pharmacodynamic model of Bcr-Abl signalling in chronic myeloid leukaemia. Cancer Chemother. Pharmacol., 2014, 74(4), 765-766.
97. [97] Milojkovic, D.; Apperley, J. Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia. Clin. Cancer Res., 2009, 15(24), 7519-7527.
98. [98] Lin, A.M.; Rini, B.I.; Derynck, M.K.; Weinberg, V.; Park, M.; Ryan, C.J.; Rosenberg, J.E.; Bubley, G.; Small, E.J. A phase I trial of docetaxel/estramustine/imatinib in patients with hormonerefractory prostate cancer. Clin. Genitourin. Cancer, 2007, 5(5), 323-328.
99. [99] Lin, A.M.; Rini, B.I.; Weinberg, V.; Fong, K.; Ryan, C.J.; Rosenberg, J.E.; Fong, L.; Small, E.J. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int., 2006, 98(4), 763-769.
100. [100] Rao, K.; Goodin, S.; Levitt, M.J.; Dave, N.; Shih, W.J.; Lin, Y.; Capanna, T.; Doyle-Lindrud, S.; Juvidian, P.; DiPaola, R.S. A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate, 2005, 62(2), 115-122.
101. [101] Yu, E.Y.; Wilding, G.; Posadas, E.; Gross, M.; Culine, S.; Massard, C.; Morris, M.J.; Hudes, G.; Calabro, F.; Cheng, S.; Trudel, G.C.; Paliwal, P.; Sternberg, C.N. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin. Cancer Res., 2009, 15(23), 7421-8.
102. [102] Phillips, R. Prostate cancer: Dasatinib fails to improve on docetaxel for metastatic CRPC. Nat. Rev. Urol. 2014, 11(1), 5.
103. [103] Ford, D.; Easton, D.F.; Bishop, D.T.; Narod, S.A.; Goldgar, D.E. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet, 1994, 343(8899), 692-695.
104. [104] Bancroft, E.K.; Page, E.C.; Castro, E.; Lilja, H.; Vickers, A.; Sjoberg, D.; Assel, M.; Foster, C.S.; Mitchell, G.; Drew, K.; Maehle, L.; Axcrona, K.; Evans, D.G.; Bulman, B.; Eccles, D.; McBride, D.; van Asperen, C.; Vasen, H.; Kiemeney, L.A.; Ringelberg, J.; Cybulski, C.; Wokolorczyk, D.; Selkirk, C.; Hulick, P.J.; Bojesen, A.; Skytte, A.B.; Lam, J.; Taylor, L.; Oldenburg, R.; Cremers, R.; Verhaegh, G.; van Zelst-Stams, W.A.; Oosterwijk, J.C.; Blanco, I.; Salinas, M.; Cook, J.; Rosario, D.J.; Buys, S.; Conner, T.; Ausems, M.G.; Ong, K.R.; Hoffman, J.; Domchek, S.; Powers, J.; Teixeira, M.R.; Maia, S.; Foulkes, W.D.; Taherian, N.; Ruijs, M.; den Enden, A.T.; Izatt, L.; Davidson, R.; Adank, M.A.; Walker, L.; Schmutzler, R.; Tucker, K.; Kirk, J.; Hodgson, S.; Harris, M.; Douglas, F.; Lindeman, G.J.; Zgajnar, J.; Tischkowitz, M.; Clowes, V.E.; Susman, R.; Ramon, Y.C.T.; Patcher, N.; Gadea, N.; Spigelman, A.; van Os, T.; Liljegren, A.; Side, L.; Brewer, C.; Brady, A.F.; Donaldson, A.; Stefansdottir, V.; Friedman, E.; Chen-Shtoyerman, R.; Amor, D.J.; Copakova, L.; Barwell, J.; Giri, V.N.; Murthy, V.; Nicolai, N.; Teo, S.H.; Greenhalgh, L.; Strom, S.; Henderson, A.; McGrath, J.; Gallagher, D.; Aaronson, N.; Ardern-Jones, A.; Bangma, C.; Dearnaley, D.; Costello, P.; Eyfjord, J.; Rothwell, J.; Falconer, A.; Gronberg, H.; Hamdy, F.C.; Johannsson, O.; Khoo, V.; Kote-Jarai, Z.; Lubinski, J.; Axcrona, U.; Melia, J.; McKinley, J.; Mitra, A.V.; Moynihan, C.; Rennert, G.; Suri, M.; Wilson, P.; Killick, E.; Moss, S.; Eeles, R.A. Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. Eur. Urol., 2014, 66(3), 489-499.
105. [105] Gallagher, D.J.; Gaudet, M.M.; Pal, P.; Kirchhoff, T.; Balistreri, L.; Vora, K.; Bhatia, J.; Stadler, Z.; Fine, S.W.; Reuter, V.; Zelefsky, M.; Morris, M.J.; Scher, H.I.; Klein, R.J.; Norton, L.; Eastham, J.A.; Scardino, P.T.; Robson, M.E.; Offit, K. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin. Cancer Res., 2010, 16(7), 2115-2121.
106. [106] Edwards, S.M.; Kote-Jarai, Z.; Meitz, J.; Hamoudi, R.; Hope, Q.; Osin, P.; Jackson, R.; Southgate, C.; Singh, R.; Falconer, A.; Dearnaley, D.P.; Ardern-Jones, A.; Murkin, A.; Dowe, A.; Kelly, J.; Williams, S.; Oram, R.; Stevens, M.; Teare, D.M.; Ponder, B.A.; Gayther, S.A.; Easton, D.F.; Eeles, R.A. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am. J. Hum. Genet., 2003, 72(1), 1-12.
107. [107] Fong, P.C.; Boss, D.S.; Yap, T.A.; Tutt, A.; Wu, P.; Mergui-Roelvink, M.; Mortimer, P.; Swaisland, H.; Lau, A.; O’Connor, M.J.; Ashworth, A.; Carmichael, J.; Kaye, S.B.; Schellens, J.H.; de Bono, J.S. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med., 2009, 361(2), 123-134.
108. [108] Edwards, S.L.; Brough, R.; Lord, C.J.; Natrajan, R.; Vatcheva, R.; Levine, D.A.; Boyd, J.; Reis-Filho, J.S.; Ashworth, A. Resistance to therapy caused by intragenic deletion in BRCA2. Nature, 2008, 451(7182), 1111-1115.
109. [109] Ashworth, A. Drug resistance caused by reversion mutation. Cancer Res., 2008, 68(24), 10021-10023.
110. [110] Beltran, H.; Yelensky, R.; Frampton, G.M.; Park, K.; Downing, S.R.; MacDonald, T.Y.; Jarosz, M.; Lipson, D.; Tagawa, S.T.; Nanus, D.M.; Stephens, P.J.; Mosquera, J.M.; Cronin, M.T.; Rubin, M.A. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur. Urol., 2013, 63(5), 920-926.
111. [111] Brenner, J.C.; Ateeq, B.; Li, Y.; Yocum, A.K.; Cao, Q.; Asangani, I.A.; Patel, S.; Wang, X.; Liang, H.; Yu, J.; Palanisamy, N.; Siddiqui, J.; Yan, W.; Cao, X.; Mehra, R.; Sabolch, A.; Basrur, V.; Lonigro, R.J.; Yang, J.; Tomlins, S.A.; Maher, C.A.; Elenitoba-Johnson, K.S.; Hussain, M.; Navone, N.M.; Pienta, K.J.; Varambally, S.; Feng, F.Y.; Chinnaiyan, A.M. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell, 2011, 19(5), 664-678.
112. [112] Hollstein, M.; Sidransky, D.; Vogelstein, B.; Harris, C.C. p53 mutations in human cancers. Science, 1991, 253(5015), 49-53.
113. [113] Roychowdhury, S.; Iyer, M.K.; Robinson, D.R.; Lonigro, R.J.; Wu, Y.M.; Cao, X.; Kalyana-Sundaram, S.; Sam, L.; Balbin, O.A.; Quist, M.J.; Barrette, T.; Everett, J.; Siddiqui, J.; Kunju, L.P.; Navone, N.; Araujo, J.C.; Troncoso, P.; Logothetis, C.J.; Innis, J.W.; Smith, D.C.; Lao, C.D.; Kim, S.Y.; Roberts, J.S.; Gruber, S.B.; Pienta, K.J.; Talpaz, M.; Chinnaiyan, A.M. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci. Transl. Med., 2011, 3(111), 111-121.
114. [114] Olaparib shows promise in multiple tumor types. Cancer Dis., 2013, 3(7), 5.
115. [115] Prensner, J.R.; Chen, W.; Iyer, M.K.; Cao, Q.; Ma, T.; Han, S.; Sahu, A.; Malik, R.; Wilder-Romans, K.; Navone, N.; Logothetis, C.J.; Araujo, J.C.; Pisters, L.L.; Tewari, A.K.; Canman, C.E.; Knudsen, K.E.; Kitabayashi, N.; Rubin, M.A.; Demichelis, F.; Lawrence, T.S.; Chinnaiyan, A.M.; Feng, F.Y. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res., 2014, 74(6), 1651-1660.
116. [116] Robinson, D.R.; Wu, Y.M.; Vats, P.; Su, F.; Lonigro, R.J.; Cao, X.; Kalyana-Sundaram, S.; Wang, R.; Ning, Y.; Hodges, L.; Gursky, A.; Siddiqui, J.; Tomlins, S.A.; Roychowdhury, S.; Pienta, K.J.; Kim, S.Y.; Roberts, J.S.; Rae, J.M.; Van Poznak, C.H.; Hayes, D.F.; Chugh, R.; Kunju, L.P.; Talpaz, M.; Schott, A.F.; Chinnaiyan, A.M. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet., 2013, 45(12), 1446-1451.